CS242310B1 - Ig-7s or igg,iga,igm containing agent for external use - Google Patents
Ig-7s or igg,iga,igm containing agent for external use Download PDFInfo
- Publication number
- CS242310B1 CS242310B1 CS118383A CS118383A CS242310B1 CS 242310 B1 CS242310 B1 CS 242310B1 CS 118383 A CS118383 A CS 118383A CS 118383 A CS118383 A CS 118383A CS 242310 B1 CS242310 B1 CS 242310B1
- Authority
- CS
- Czechoslovakia
- Prior art keywords
- iga
- igg
- parts
- weight
- igm
- Prior art date
Links
Landscapes
- Medicinal Preparation (AREA)
Abstract
Vynález sa týká .přípravku pre vonkajšie použitie, ktorý obsahuje Ig-7S alebo zmesi IgG, IgA a IgM v methyleelulózovom základe. Zložky zmesi sú v nasledujúcom pomere: 5,0 až 20,0 hmotnostných dielov uvedených imunoglobulínoiv v 1 000 hmotnostných dielov uvedených základov. Lokálna aplikácia imunoglobulínov představuje nové liečebné možnosti zápalových ochorení tělesného povrchu.The invention relates to an external formulation use comprising Ig-7S or mixtures thereof IgG, IgA, and IgM in methyleululose base. The ingredients of the mixture are as follows: 5.0 to 20.0 parts by weight immunoglobulins in 1000 wt parts of the foundations. Topical application of immunoglobulins new therapeutic options for inflammatory body surface diseases.
Description
Vynález sa týká zloženia přípravku Ig-7S alebo zmesi IgG, IgA, IgM pre vonkajšie použitie, kde nosičem imunoglobulínov sú metylcelulózové hydrogély, alebo masťové základy. Imunoglobulíiny v uvedených nosičoch sú bud' čisté, alebo v ikombinácii s lokálně používanými antibiotikami.The invention relates to a composition of an Ig-7S preparation or a mixture of IgG, IgA, IgM for external use, wherein the carrier of the immunoglobulins is methylcellulose hydrogels or ointment bases. The immunoglobulins in said carriers are either pure or in combination with topically used antibiotics.
V súčasnoím období v kožnom lekárstve, septickej chirurgii použlvajú sa hydrogély a masti obsahujúce antibiotiká. Tvorba rezlstencle mikreorganizmev na lokálně podávané antibiotiká je značná. Lokálna apllkácia imunoglobulínov představuje nové liečebné možnosti zápalových ochorení tělesného povrchu mikrobiálně ekcémy, flegmóny róznej lokalizácie, bércové vředy, chronické osteomyeliitídy — nakolko dochádza ku synergickému účinku s antibiotikami. Potenciovanie účinku antibiotik imunoglobuUnami popisuje Ronmeberger a Zwisler 1982. (Ronneberg H. Zwisler O.: Fortschritte auf dem Gebiet der Antibiotika — und Immunotherapie, A. K. Klelnschmidt und S. Raptis vydav., Urban a Schwarzeinberg, Munchen 1982).At present, hydrogels and ointments containing antibiotics are used in dermatology, septic surgery. The formation of rezlstencle mikreorganizmev on topically administered antibiotics is considerable. Local application of immunoglobulins presents new treatment options for inflammatory diseases of the body surface by microbial eccemas, phlegmons of differentiated localization, leg ulcers, chronic osteomyeliitis - because of the synergistic effect with antibiotics. Potentiating the effect of immunoglobulin antibiotics is described by Ronmeberger and Zwisler 1982. (Ronneberg H. Zwisler O .: Fortschritte auf dem Gebiet der Antibiotik- und Immunotherapie, A.K. Klelnschmidt und S. Raptis ed., Urban and Schwarzeinberg, Munchen 1982).
Podstata vynálezu spočívá v tom, že přípravek obsahuje Ig v množstve 3,8—20,0 g opracovaných 1 000 g do 3—5 hmotnostných %! metylceilulózového alebo masťového základu.The present invention is characterized in that the composition comprises Ig in an amount of 3.8-20.0 g of treated 1000 g to 3-5% by weight . methylceilulose or ointment base.
Získaná zmes sa homogeinizuje a rozplňuje do balení po 10 a 50 g.The mixture obtained is homogenized and filled into packs of 10 and 50 g.
V případe, že do zmesi přidáváme aj antibiotiká použijeme tieto koncentrácie na 100 g masťového základu, alebo metylcelulózového hydrogélu.If antibiotics are added to the mixture we use these concentrations per 100 g ointment base or methylcellulose hydrogel.
Bacltracín Chlor ampheinicol Neomycín Nystatin Trichomycin Tyrothricin Gentamycin Příklad prevedenia:Bacltracin Chlorine ampheinicol Neomycin Nystatin Trichomycin Tyrothricin Gentamycin Example:
575 000 j. 0,25-2,5 g 0,25-2,0 g575,000 0.25-2.5 g 0.25-2.0 g
5—15 000 000 j. 10—20 000 000 j. 25-75 mg5—15 000 000 units 10—20 000 000 units 25-75 mg
80—240 mg80—240 mg
500 mg imunoglobulínov 7S alebo zmesi IgG, IgA, IgM sa rozpustí v 10 g aqua pri inj. ČsL—3 a zmieša s 30 g masťového základu č. III pre antibiotiká o zložení:500 mg of 7S immunoglobulins or a mixture of IgG, IgA, IgM are dissolved in 10 g of aqua at injection. ČsL — 3 and mixed with 30 g ointment base no. III for antibiotics containing:
Alkohol cetylicus 1,0 gAlcohol cetylicus 1.0 g
Cera alba 1,0 gCera alba 1.0 g
Cera lané 10,0 gCereal rope 10.0 g
Vaselina alba 20,0 gVaselina alba 20.0 g
1000 mg imunoglobulínu 7S alebo zmesi IgG, IgA, IgM sa rozpustí v 20 g aqua pre inj. GsL—3 a přidá sa do 80 g 3—5 % metyle elulózovéhio hydrogélu.1000 mg of immunoglobulin 7S or a mixture of IgG, IgA, IgM is dissolved in 20 g of aqua for inj. GsL-3 and added to 80 g of 3-5% methyl cellulose hydrogel.
Obe získané zmesi sa homogenizujú a rozplňujú do balení po 10 a 50 g.The two mixtures obtained are homogenized and filled into packages of 10 and 50 g, respectively.
Claims (2)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CS118383A CS242310B1 (en) | 1983-02-22 | 1983-02-22 | Ig-7s or igg,iga,igm containing agent for external use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CS118383A CS242310B1 (en) | 1983-02-22 | 1983-02-22 | Ig-7s or igg,iga,igm containing agent for external use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CS242310B1 true CS242310B1 (en) | 1986-04-17 |
Family
ID=5345580
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CS118383A CS242310B1 (en) | 1983-02-22 | 1983-02-22 | Ig-7s or igg,iga,igm containing agent for external use |
Country Status (1)
| Country | Link |
|---|---|
| CS (1) | CS242310B1 (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT402789B (en) * | 1991-03-25 | 1997-08-25 | Immuno Ag | PHARMACEUTICAL PREPARATION BASED ON PLASMA PROTEINS |
-
1983
- 1983-02-22 CS CS118383A patent/CS242310B1/en unknown
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AT402789B (en) * | 1991-03-25 | 1997-08-25 | Immuno Ag | PHARMACEUTICAL PREPARATION BASED ON PLASMA PROTEINS |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5973002A (en) | Prostaglandin E1 derivatives as pharmacologically active agents, especially for transcutaneous administration | |
| AU619772B2 (en) | Improvements in or relating to organic compounds | |
| US5529987A (en) | Hyaluronic acid-urea pharmaceutical compositions and uses | |
| US4722936A (en) | Deodorization vaginal products and catamenials | |
| EP0292893B2 (en) | Steroid lotion | |
| EP0257025A1 (en) | Antitoxin vaginal products and catamenials comprising ascorbic acid | |
| CZ286821B6 (en) | Use of fumagillol or ester thereof for preparing medicaments intended for fighting intestinal infections | |
| DE69430132D1 (en) | PERNASAL COMPOSITION AND PERNASALE PREPARATION CONTAINING IT | |
| US3758686A (en) | Method of using steroid acetonides | |
| Ancona et al. | Allergic contact dermatitis from povidoneiodine | |
| WO1988005298A1 (en) | Use of anorectal compositions | |
| US4725590A (en) | Method of relieving pain and inflammatory conditions employing substituted salicylamides | |
| AU623028B2 (en) | Pharmaceutical composition for topic use for the therapeutical treatment of capillary fragility | |
| ZA200505174B (en) | Pharmaceutical compositions comprising a combination of calcitriol and a clobetasol propionate | |
| NZ251424A (en) | Pharmaceutical composition comprising folic acid, panthenol, allantoin, protein hydrolysate, lactose or dextrose, lactic acid, magnesium sulphate and sodium or ammonium chloride | |
| EP0352826B1 (en) | Use of 5-aminosalicylic acid in the treatment of dermatological disorders | |
| US3777020A (en) | Psoriasis treatment with mycophenolic acid | |
| CS242310B1 (en) | Ig-7s or igg,iga,igm containing agent for external use | |
| EP0535446A1 (en) | Pharmaceutical compositions for topical use containing a chelating agent, a tocopheral and an antimicrobial agent | |
| AU2003294027B2 (en) | Pharmaceutical compositions comprising a combination of calcitriol and a clobetasol propionate | |
| DE651654T1 (en) | LYSOZYME DIMER AND PREPARATIONS THAT CONTAIN IT. | |
| JP4124495B2 (en) | Local anesthetic composition | |
| EP0365613A1 (en) | Combination of tobramycin and steroids for topical ophthalmic use. | |
| US3937822A (en) | Method for treating psoriasis | |
| IL35341A (en) | Antibiotic synergistic compositions containing primycin and another antibiotic and their preparation |